Bausch + Lomb (BLCO)

• Market cap: $4.26B
• 1 day: -0.08%
• 5 days: 3.61%
• 1 month: -22.56%
• 3 months: -29.86%
• 6 months: -41.73%
• Year to date: -33.06%
• 1 year: -17.69%
• 5 years: -39.75%
• 10 years: -39.75%
• Sector: Healthcare
• Industry: Medical Instruments & Supplies

About: Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Employees: 13,500

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

21% more call options, than puts

Call options by funds: $5.9M | Put options by funds: $4.89M

20% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 25

2% more funds holding

Funds holding: 110 [Q3] → 112 (+2) [Q4]

0% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 32

1.02% less ownership

Funds ownership: 10.74% [Q3] → 9.71% (-1.02%) [Q4]

15% less capital invested

Capital invested by funds: $729M [Q3] → $618M (-$111M) [Q4]

71% less funds holding in top 10

Funds holding in top 10: 7 [Q3] → 2 (-5) [Q4]

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $15 24% upside
• Avg. target: $17 41% upside
• High target: $20 66% upside

6 analyst ratings

• positive: 2 33%
• neutral: 3 50%
• negative: 1 17%

RBC Capital Douglas Miehm 40% 1-year accuracy 10 / 25 met price target	41% upside $17	Outperform Maintained	4 Apr 2025
Stifel	24% upside $15	Hold Maintained	3 Apr 2025
Wells Fargo Larry Biegelsen 24% 1-year accuracy 11 / 46 met price target	24% upside $15	Equal-Weight Downgraded	28 Mar 2025
HC Wainwright & Co. Yi Chen 28% 1-year accuracy 48 / 172 met price target	66% upside $20	Buy Maintained	21 Feb 2025
B of A Securities Craig Bijou 67% 1-year accuracy 6 / 9 met price target	41% upside $17	Underperform Maintained	20 Feb 2025